Cover Image
市場調查報告書

滑囊肉瘤:開發平台分析

Synovial Sarcoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 321902
出版日期 內容資訊 英文 141 Pages
訂單完成後即時交付
價格
Back to Top
滑囊肉瘤:開發平台分析 Synovial Sarcoma - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 141 Pages
簡介

滑囊肉瘤是生於軟組織的腫瘤,一般分爲雙相型和單相型,由表皮細胞或紡錘細胞所形成。

本報告提供滑囊肉瘤的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

目錄

簡介

滑囊肉瘤概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • Adaptimmune Therapeutics Plc
  • Advenchen Laboratories, LLC
  • EpiZyme, Inc.
  • Immune Design Corp.
  • Karyopharm Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OncoTherapy Science, Inc.
  • TaKaRa BIO Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AL-3818
  • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology
  • CMB-305
  • everolimus
  • GSK-3377794
  • OTSA-101
  • pembrolizumab
  • selinexor
  • SSTC-104
  • tazemetostat
  • TBI-1301

開發中產品的最新趨勢

開發中止的計劃

產品開發的里程碑

  • 關注的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8375IDB

Summary

Global Markets Direct's, 'Synovial Sarcoma - Pipeline Review, H2 2016', provides an overview of the Synovial Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma
  • The report reviews pipeline therapeutics for Synovial Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Synovial Sarcoma therapeutics and enlists all their major and minor projects
  • The report assesses Synovial Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Synovial Sarcoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Synovial Sarcoma Overview
  • Therapeutics Development
    • Pipeline Products for Synovial Sarcoma - Overview
    • Pipeline Products for Synovial Sarcoma - Comparative Analysis
  • Synovial Sarcoma - Therapeutics under Development by Companies
  • Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes
  • Synovial Sarcoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Synovial Sarcoma - Products under Development by Companies
  • Synovial Sarcoma - Products under Investigation by Universities/Institutes
  • Synovial Sarcoma - Companies Involved in Therapeutics Development
    • Adaptimmune Therapeutics Plc
    • Advenchen Laboratories, LLC
    • EpiZyme, Inc.
    • Immune Design Corp.
    • Immunocore Limited
    • Karyopharm Therapeutics, Inc.
    • Merck & Co., Inc.
    • Millennium Pharmaceuticals Inc
    • Novartis AG
    • OncoTherapy Science, Inc.
    • Pfizer Inc.
    • Takara Bio Inc.
  • Synovial Sarcoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ACXT-3102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AL-3818 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • axitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMB-305 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3377794 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OTSA-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapanisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SSTC-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tazemetostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TBI-1301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Synovial Sarcoma - Discontinued Products
  • Synovial Sarcoma - Product Development Milestones
    • Featured News & Press Releases
      • Feb 22, 2016: The completion of phase I clinical study of the anti-cancer therapeutic antibody 'OTSA101' against synovial sarcoma
      • Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors
      • Aug 24, 2015: Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma
      • Oct 17, 2014: Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma
      • Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US
      • Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Synovial Sarcoma, H2 2016
  • Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Synovial Sarcoma - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Synovial Sarcoma - Pipeline by EpiZyme, Inc., H2 2016
  • Synovial Sarcoma - Pipeline by Immune Design Corp., H2 2016
  • Synovial Sarcoma - Pipeline by Immunocore Limited, H2 2016
  • Synovial Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Synovial Sarcoma - Pipeline by Merck & Co., Inc., H2 2016
  • Synovial Sarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Synovial Sarcoma - Pipeline by Novartis AG, H2 2016
  • Synovial Sarcoma - Pipeline by OncoTherapy Science, Inc., H2 2016
  • Synovial Sarcoma - Pipeline by Pfizer Inc., H2 2016
  • Synovial Sarcoma - Pipeline by Takara Bio Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Synovial Sarcoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Synovial Sarcoma, H2 2016
  • Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top